Send the following on WhatsApp
Continue to ChatCASPIAN is an ongoing, open-label, sponsor-blind, randomized, controlled phase 3 trial at 209 cancer treatment centers in 23 countries. Eligible patients were aged 18 years or older with extensive-stage small-stage lung cancer (ES-SCLC). https://www.umdaa.co/blogs/117/durvalumab-with-or-without-tremelimumab-plus-platinumetoposide-versus-platinumetoposide-alone-in-first-line-treatment-of-extensive-stage-small-cell-lung-cancer-caspian-updated-results-from-a-randomised-controlled-open-label-phase-3-trial